Background: Narcolepsy is a rare neurological disease caused by dysfunction of hypocretin-producing neurons. Hypocretin concentrations in the cerebrospinal fluid (CSF) of less than 110 pg/ml are considered pathological in adults.
Objectives: To compare hypocretin levels of children with narcolepsy type 1, type 2 and disease control groups, in addition to a detailed CSF analysis, clinical and polysomnographic parameters.
Methods: In a retrospective, cross-sectional study, children diagnosed with narcolepsy based on clinical and polysomnographic parameters, who received a CSF analysis and hypocretin measurement, in addition to controls, were included. CSF was analyzed for the presence of cells, total protein, lactate, intrathecal synthesis of antibodies against measles, rubella and/or varicella zoster, and oligoclonal bands. All children had a complete sleep study including a multiple sleep latency test (MSLT).
Results: 49 children with narcolepsy type 1, 15 children with type 2 and 37 children with other (suspected) neurological diseases were included. CSF routine analysis did not reveal any differences between the three groups. All children with narcolepsy type 1 had hypocretin levels of less than 110 pg/ml (range: 10-101 pg/ml). Hypocretin levels in type 2 patients ranged from 43 to 436 pg/ml (median 157 pg/ml). The median hypocretin level in the control cohort was 365 pg/ml (range: 153-583 pg/ml). In 4 children with narcolepsy type 2 the diagnosis was changed to narcolepsy level 1 because of a CSF hypocretin level of less than 110 pg/ml according to the recently proposed criteria, which consider the measurement of hypocretin in CSF.
Conclusion: Children with narcolepsy type 1 showed significantly lower CSF hypocretin levels than children with narcolepsy type 2 and controls. As suggested by the recently published narcolepsy criteria, hypocretin levels of less than 110 pg/ml should be used as an additional criterion for the presence of narcolepsy type 1 in children.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejpn.2024.08.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology, patient characteristics, and treatment patterns of patients with narcolepsy in Sweden: a non-interventional study using secondary data.
Sleep Adv
December 2024
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Study Objectives: To estimate the prevalence and incidence and evaluate the treatment patterns of patients diagnosed with narcolepsy in specialist care in Sweden.
Methods: This non-interventional retrospective longitudinal study used Swedish register data from 2010 to 2020 and included patients diagnosed with narcolepsy (either type 1 or type 2), recorded in specialist outpatient and inpatient care from January 2015 to December 2019. All patients received an index date corresponding to the date of the first narcolepsy diagnosis.
Armodafinil as Monotherapy in Treating Narcolepsy with Cataplexy.
Cureus
December 2024
Internal Medicine, Guthrie Lourdes Hospital, Binghamton, USA.
In narcolepsy with cataplexy, sodium oxybate and the recently FDA-approved drug pitolisant are preferred medications. Armodafinil, a longer-acting, non-amphetamine stimulant, is often used in patients who have narcolepsy without cataplexy. It enhances alertness by increasing presynaptic dopamine transmission presynaptically, amplifying serotonin in the cerebral cortex, activating glutamatergic circuits, which may contribute to its vigilance-enhancing properties, and stimulating orexin activity.
View Article and Find Full Text PDFOfatumumab treatment in new-onset narcolepsy type 1 following SARS-CoV-2 infection.
Ann Clin Transl Neurol
December 2024
Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Objectives: To explore the efficacy of ofatumumab in new onset narcolepsy type 1 following SARS-CoV-2 infection.
Methods: We present a 9-year-old girl who experienced new onset narcolepsy type 1 following SARS-CoV-2 infection. Polysomnography (PSG) followed by a daytime multiple sleep latency test (MSLT) was under taken after admission.
Impaired Vigilance in Patients with Narcolepsy Type 1: A Psychomotor Vigilance Task Study.
Nat Sci Sleep
December 2024
Department of Neurology and Center for Sleep Medicine, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Purpose: The psychomotor vigilance task (PVT) is one of the main methods to measure sustained vigilance/attention in sleep research. Vigilance is the main factor affecting daytime function in patients with narcolepsy type 1 (NT1). We aimed to quantify the negative effects of sleep-wake disorders on vigilance and investigate potential neural mechanisms.
View Article and Find Full Text PDFCorticosteroid-responsive narcolepsy type II after COVID-19: A relevant differential diagnosis of post-COVID syndrome (a case report).
J Sleep Res
December 2024
Department of Neurology, Jena University Hospital, Jena, Germany.
Article Synopsis
- Excessive daytime sleepiness can be a symptom of post-COVID syndrome and narcolepsy, a rare sleep disorder that may have an autoimmune cause.
- A case study of a 25-year-old male showed he developed narcolepsy type II after COVID-19, confirmed through sleep tests and neuropsychological evaluations.
- Treatment with high-dose corticosteroids led to an immediate improvement in his symptoms, suggesting that immunosuppressive therapy might be a viable option for managing narcolepsy following COVID-19.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!